Search

The use of computed tomography perfusion (CTP), one of the multimodal imaging uncorrected proof modalities, has recently become an important tool in determining endovascular treatment candidates in stroke centers. However, the reliability of CTP in identifying the infarct core may vary depending on the time of symptom onset, collateral status, and other clinical factors. In some studies, it has been determined that showing the penumbra with CTP imaging increases the chance of success in the selection of patients for endovascular treatment. The difference in sensitivity to hypoxia in the brain parenchyma (such as white and gray matter) makes it difficult to determine the ischemic tissue response, thus increasing the importance of perfusion studies. Accordingly, many automatic software programs have been used with CTP imaging. Among these, RAPID (iSchemaView, Menlo Park, California, USA) and Olea Sphere (Olea Medical Solutions, La Ciotat, France) are among the most frequently used. The rates of each of these programs showing the infarct core and the probability of error have been discussed by different studies. In this article, we aim to evaluate the role of CTP imaging in the treatment process before deciding on whether to deliver endovascular treatment for a 55-year-old female patient who presented with right-middle cerebral artery infarction clinic and had a wake-up stroke. [ABSTRACT FROM AUTHOR]

Objective: This study aims to evaluate data from coronavirus disease-2019 (COVID-19) patients with neurological manifestations hospitalized in the intensive care unit (ICU). Materials and Methods: The study included data from COVID-19 patients with neurological manifestations hospitalized in ICU. Patients' demographic characteristics, risk factors, laboratory results, treatment methods, mechanical ventilation methods, use of non-invasive techniques to meet O2 requirements, clinical outcome at discharge and after three months, and mortality rates were evaluated. Results: The study included 25 patients. Mean age of the patients was 66.76±12.93. Fifty two percent of the patients were male. Of the patients 96% had a positive polymerase chain reaction test, and 92% had lung involvement. The comorbidities of the patients were hypertension (48%), diabetes mellitus (28%), coronary artery disease (28%), cerebrovascular disease (20%), cancer (20%), and chronic obstructive pulmonary disease (12%). Seventy two percent of the patients presented with stroke. Of the patients %12 presented with encephalopathy, whereas patients with epilepsy and myasthenia gravis accounted for 8%. Patients' average length of stay in ICU was 13.16±12.44 days. Pressure-synchronized intermittent mandatory ventilation mode was used in 56% of patients. Number of intubation days was 9.5±12.26. All patients were treated with favipiravir and antiaggregant, 92% with steroids and antibacterial therapy, 52% with antiaggregant, 20% with plasma therapy, 8% with cytokine filter and immunoglobulin therapy, and 4% with monoclonal antibody therapy. During hospitalization, mortality rate was 48%, good clinical outcome rate was 36%. Conclusion: The rates of poor clinical outcomes are seen to be high during in-hospital treatment and follow-up of COVID-19 patients presenting with neurological symptoms, as well as at discharge. [ABSTRACT FROM AUTHOR]